539-93-5

Basic information

• Product Name: ALPHA,ALPHA'-DILAURIN
• Synonyms: DILAURIN 1-3 ISOMER;GLYCEROL ALPHA,ALPHA'-DILAURATE;GLYCEROL DILAURATE;GLYCERYL DILAURATE;1,3-DILAURIN;1,3-DILAURIN (C12:0);1,3-DIDODECANOYLGLYCEROL;ALPHA,ALPHA'-DILAURIN
• CAS NO: 539-93-5
• Molecular Formula: C27H52O5
• Molecular Weight: 456.7
• EINECS: 208-731-9
• Mol File: 539-93-5.mol
• Article Data: 24

Chemical Properties

• Melting Point: 59 °C
• Boiling Point: 539.9 °C at 760 mmHg
• Flash Point: 161.6 °C
• Appearance: white to slightly off-white crystalline powder
• Density: 0.953 g/cm³
• Vapor Pressure: 6.56E-14mmHg at 25°C
• Refractive Index: 1.463
• Storage Temp.: −20°C
• Solubility: Acetonitrile (Slightly), Chloroform (Slightly)
• PKA: 12.63±0.20(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: ALPHA,ALPHA'-DILAURIN(CAS DataBase Reference)
• NIST Chemistry Reference: ALPHA,ALPHA'-DILAURIN(539-93-5)
• EPA Substance Registry System: ALPHA,ALPHA'-DILAURIN(539-93-5)

Safety Data

• WGK Germany: 1
• F: 10-21
• Hazardous Substances Data: 539-93-5(Hazardous Substances Data)

Usage

Uses

α,α''-Dilaurin is a possible antimicrobial agent against gram-posistive organisms.

InChI:InChI=1/C27H52O5/c1-3-5-7-9-11-13-15-17-19-21-26(29)31-23-25(28)24-32-27(30)22-20-18-16-14-12-10-8-6-4-2/h25,28H,3-24H2,1-2H3

Upstream product

• 112-16-3 n-dodecanoyl chloride 
• 40738-26-9 rac-1-monolauroylglycerol 
• 2146-71-6 vinyl laurate 
• 56-81-5 glycerol 
• 143-07-7 lauric acid 
• 96-23-1 1,3-Dichloro-2-propanol 
• 10124-65-9 potassium laurate 
• 96-26-4 dihydroxyacetone 
• 931-40-8 4-hydroxymethyl-1,3-dioxolan-2-one 
• 645-66-9 lauric anhydride 
• 538-24-9 tridodecanoylglycerol 
• 17598-94-6 glyceryl dilaurate 
• 111-82-0 methyl n-dodecanoate 
• 861542-51-0 acidic glycerol-1.3-disulfate 

Downstream Products

• 51464-76-7 β'-1,3-didodecanoyl-2-tetradecanoyl-glycerol 
• 59925-19-8 2-Indomethacoyl-1,3-didodecanoylglycerin 
• 40738-26-9 rac-1-monolauroylglycerol 
• 1678-45-1 glycerol laurate 
• 17598-94-6 glyceryl dilaurate 
• 56-81-5 glycerol 
• 82058-15-9 Dodecanoic acid 2-[2-(4-allyloxy-3-chloro-phenyl)-acetoxy]-3-dodecanoyloxy-propyl ester 
• 106386-01-0 1.3-Di-O-lauroyl-glycerin-2- 
• 93378-79-1 1,3-bis-lauroyloxy-2-palmitoyloxy-propane 
• 51067-90-4 1,3-dilauroyl-2-oleyl-glycerol 

Relevant articles and documents

Synthesis of 2-Modified 1,3-Diacylglycerols

1,3-Diacylglycerols modified in 2-position were synthesized by combining enzymatic and chemical methods.The syntheses started from the regioisomerically pure 1,3-dilauroylglycerol or 1,3-dimyristoylglycerol obtained from glycerol and vinyl esters of carboxylic acids by means of lipase from Mucor mihei.The 2-hydroxyl group in the glycerol derivatives was subsequently substituted by phosphate as well as its disodium salt, by sulfate, phosphocholine, the benzyloxy, the succinimidyl or the amino group.

METHOD FOR PREPARING MONOGLYCERIDES

The present application relates to a method for preparing monoglycerides, a method for recovering glycerin and catalysts after the process for preparing monoglycerides, and a process for preparing cyclic monoglycerides.(AA) Fatty acid glycerin catalyst(BB) Esterification(CC) Reuse(DD) Settling and separation(EE) Glycerin and most of catalyst(F1,F2) Glyceride layer(GG) Glycerin(HH) Washing and separation(II) Glycerin and traces of catalyst(JJ) Glyceride layer(KK) Molecular distillation(LL) Glycerin and unreacted fatty acid(MM) Di- and tri-glycerideCOPYRIGHT KIPO 2020

COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.